News about "antibody therapy "

ADEL Signs USD 1.04 Billion Global Licensing Deal with Sanofi for Alzheimer's Drug

ADEL Signs USD 1.04 Billion Global Licensing Deal with Sanofi for Alzheimer's Drug

ADEL has signed a global licensing deal with Sanofi for its investigational Alzheimer’s therapy ADEL-Y01, valued at up to USD 1.04 billion, including a USD 80 million upfront payment, milestone payments and royalties.

Antibody Therapy | 16/12/2025 | By News Bureau

Novo Nordisk Secures Rights from Omeros to Develop Rare Disease Drug Zaltenibart in USD 2.1 Billion Deal

Novo Nordisk Secures Rights from Omeros to Develop Rare Disease Drug Zaltenibart in USD 2.1 Billion Deal

Danish drugmaker Novo Nordisk has entered into a definitive asset purchase and license agreement with US-based Omeros Corporation for zaltenibart (formerly OMS906), a clinical-stage antibody therapy being developed for rare blood and kidney disorders.

Antibody Therapy | 16/10/2025 | By Dineshwori 146


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members